Organisation paid for research Program year 2021 Source: CMS Open Payments

Integratrials LLC

Neither a doctor nor a teaching hospital

Research payments

$171,069

88 payments

Through program year 2021, Integratrials LLC is reported as receiving $171,069 in research payments, across 88 payments.

By program year

3 rows

Year	Kind	Amount	Payments
2021	Research	$8,262	17
2020	Research	$45,143	22
2019	Research	$117,663	49

Breakdown

Who paid Research payments · program years 2019–2021

Akebia Therapeutics Inc $79,958 80 payments
Fidia Pharma USA Inc. $61,660 6 payments
Otsuka Pharmaceutical Development & Commercialization, Inc. $22,755 1 payment
AstraZeneca Pharmaceuticals LP $6,696 1 payment

Studies the money was for Research payments · program years 2019–2021

Eqe7-16-01 $55,010 3 payments
Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Correction of Anemia in Subjects With Non-Dialysis-Dependent Chronic Kidney Disease (Ndd-Ckd) (Pro2tect-Correction) $34,918 14 payments
Akb-6548-Ci-0014 $31,019 41 payments
A Phase 3B, Multi-Center, Open-Label Trial to Evaluate the Long Term Safety of Titrated Immediate-Release Tolvaptan Opc-41061, 30 MG to 120 Mgday, Split Dose in Subjects With Autosomal Dominant Polycystic Kidney Disease $22,755 1 payment
Akb-6548-Ci-0014 $6,877 16 payments
A Multinational Randomised Double Blind Placebo Controlled Trial to Evaluate the Effect of Ticagrelor 90 mg twice daily on the Incidence of Cardiovascular Death Myocardial Infarction or Stroke in Patients with Type 2 Diabetes $6,696 1 payment
Active $6,650 3 payments
Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Maintenance Treatment of Anemia in Subjects With Non-Dialysis-Dependent Chronic Kidney Disease (Ndd-Ckd) (Pro2tect-Conversion) $3,575 5 payments
Akb-6548-Ci-0015 $2,184 3 payments
Akb-6548-Ci-0015 $1,385 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.